At-Home Dialysis; Patients Have New Treatment Flexibility
Peginesatide, an erythropoiesis-stimulating agent (ESA) intended for once-a-month treatment of anemia due to chronic kidney disease, has been approved for use in adults undergoing dialysis, FDA, Affymax Inc., and Takeda Pharmaceutical Company Limited announced March 27.Affymax has described the drug...
A new modem-based communication link for pediatric home peritoneal dialysis patients Home peritoneal dialysis (PD) is often the only treatment option for children with chronic renal failure who live a significant distance from a pediatric hemodialysis center. Over the past 10 years, we have been wo...
The Product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients. Desidustat Tablets have been approved for marketing in India. CMS...
In the United Kingdom at least 7% of the adult population have an eGFR of less than 60mls/min and over forty thousand patients are receiving treatment for end stage renal disease (ESRD) [1], with an increasingly aging population suffering from a significant number of co- morbidities these ...
On January 1, 2011, the CMS fundamentally changed payment for dialysis services for Medicare patients with ESRD by making a single bundled payment (the expanded PPS) for each dialysis treatment to cover dialysis-related items and services.1 This has replaced the prior system that made a single ...
Dr Krishnan said the team started providing treatment at the new facility about three weeks ago. He said they had had 13 patients on dialysis already and admissions and the numbers kept increasing because kidney patients who used to travel to Suva and Lautoka for treatment now visited the hub ...
O-075: Burden of comorbidity of older subjects on dialysis: the QiN registry G. von Gersdorff, M.C. Polidori, M. Schaller, K. Rascher, ... G. Roehrig Pages S26-S27 select article O-076: Health related quality of life (HRQOL) in older patients waiting for kidney transplantation in ...
*Conclusions:The use of the new potassium lowering agents appears to be safe in the early post-transplant period. The use of potassium binders does not appear to be associated with reduced number of dialysis sessions in patients wi...
hyperlipidemia (p= 0.0007), which shows that the higher the dose, the more significant the protective effect. Because there were only 404 dialysis patients and there were only few patients with dialysis who were diagnosed sarcopenia with usage of statins, so they were not statistically analyzed. ...